SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
Chouieri, Toni
The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S12 [Periódico revisado por pares]US: Oxford University Press
Texto completo disponível